Simulations Plus

Multiprotic ionization is often poorly understood in the pharmaceutical industry.

In the Ionization Prediction Summit webinar series, leading industry experts will explain ionization, how ionization modeling works, how ionization models are influenced by the large amounts of industrial data...

Your model is only as good as your data!

One of the key areas for optimization in the drug development process is the discovery stage. Traditional methods are time-consuming and often produce leads that ultimately fail.

During this webinar, we will shed light on the key benefits and practical implications of utilizing in-silico modeling for formulation development, biopharmaceutical predictions, and bioequivalence studies.

Quantitative systems pharmacology (QSP) is no longer an “emerging field.”

Modeling and simulation offer useful predictions that can help guide your drug development program—but what if you could get even more out of the available technology?

During this webinar, we will shed light on the key benefits and practical implications of utilizing in silico modeling for formulation optimization, biopharmaceutical predictions, and bioequivalence studies

Your competitors are using AI and machine learning for ADMET prediction—are you?

In this webinar, Dr. Jeremy Jones, Principal Scientist, will discuss how artificial intelligence (AI) can be used in the drug discovery and development process to identify viable candidate molecules and shorten time to market.

If you’re curious how GastroPlus could be used to define dissolution safe space for your own projects, stream now.

Physiologically based pharmacokinetic (PBPK) models represent animals and humans virtually as a collection of organs and tissues, each defined by a system of mathematical equations

Discover the new functionalities of MonolixSuite 2023 in this webinar!

Join us in this webinar to learn about the technical advances made to the NAFLDsym platform in the latest release: version 2B Beta.

Learn about the new and improved functionality to drive advances to PBBM/PBPK applications from discovery through post-approval.

Students have an increased interest in learning physiologically based pharmacokinetic (PBPK) modeling, but this requires an in-depth understanding of biopharmaceutics and pharmacokinetics.

Dr. Brian P. Booth and Dr. Hao Zhu from the Office of Clinical Pharmacology (OCP) at the FDA will present and discuss Project Optimus, an initiative from the Oncology Center of Excellence (OCE) to reform the dose optimization and dose selection paradigm in oncology drug development.

Role of PBPK in Pediatric Drug Development

Simulations Plus is excited to share some technical advances that have been made to two of the feature models developed by the DILIsym Services division!